Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | ABL2 | P42684 | 2/20 | 0.53 |
| ▸ | FYN | P06241 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898154 | 0.83 | SRC (0.72) | SRCABL1ABL2FYNEGFR | |
| SCHEMBL14399424 | 0.77 | SRC (0.58) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL4901483 | 0.75 | SRC (0.71) | SRCABL1ABL2FYNEGFR | |
| SCHEMBL4899282 | 0.69 | SRC (1.00) | SRCABL1ABL2FYNEGFR | |
| SCHEMBL4764821 | 0.69 | SRC (0.51) | SRCABL1ABL2FYNEGFR | |
| SCHEMBL3222680 | 0.68 | SRC (1.00) | SRCABL1ABL2FYNEGFR | |
| SCHEMBL2896139 | 0.67 | SRC (0.69) | SRCABL1ABL2FYNEGFR | |
| SCHEMBL7148997 | 0.67 | SRC (0.73) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL4897862 | 0.67 | SRC (0.72) | SRCABL1ABL2FYNEGFR | |
| SCHEMBL4903683 | 0.67 | SRC (0.70) | SRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | BOSCHELLI DIANE H | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, TNNI3K, PKN1 | SRC 242/4885ABL1 60/4885ABL2 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.